Wilzin

RSS

zinc

Authorised
This medicine is authorised for use in the European Union.

Overview

This is a summary of the European public assessment report (EPAR). It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the studies performed, to reach its recommendations on how to use the medicine.

If you need more information about your medical condition or your treatment, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. If you want more information on the basis of the CHMP recommendations, read the scientific discussion (also part of the EPAR).

This EPAR was last updated on 14/06/2019

Authorisation details

Product details
Name
Wilzin
Agency product number
EMEA/H/C/000535
Active substance
zinc
International non-proprietary name (INN) or common name
zinc
Therapeutic area (MeSH)
Hepatolenticular Degeneration
Anatomical therapeutic chemical (ATC) code
A16AX05
OrphanOrphan

This medicine was designated an orphan medicine. This means that it was developed for use against a rare, life-threatening or chronically debilitating condition or, for economic reasons, it would be unlikely to have been developed without incentives. For more information, see Orphan designation.

Publication details
Marketing-authorisation holder
Recordati Rare Diseases
Revision
11
Date of issue of marketing authorisation valid throughout the European Union
12/10/2004
Contact address

Immeuble le Wilson
70, avenue du Général de Gaulle
92800 Puteaux
France

Product information

16/05/2019 Wilzin - EMEA/H/C/000535 - IG/1085/G

Contents

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Other alimentary tract and metabolism products

Therapeutic indication

Treatment of Wilson's disease.

Assessment history

How useful was this page?

Add your rating
Average
1 rating